Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. has demonstrated the ability of its RaniPill technology to successfully and consistently deliver biologics orally with enhanced bioavailability, supporting its advancement toward human trials in 2025. The partnership with Chugai reflects strong validation from a major player in the pharmaceutical industry and positions Rani to capture a significant market opportunity in the oral drug delivery space. Additionally, the company's robust financial position, with a cash runway extending through 2028, provides the necessary resources to advance its development programs, particularly RT-114, which may attract a larger audience in the obesity treatment market.

Bears say

Rani Therapeutics Holdings Inc. faces a negative outlook primarily due to concerns surrounding its revenue forecasts, which may be adversely impacted by competition within the biotherapeutics market and the company's ability to secure necessary reimbursement levels for its innovative drug delivery methods. Despite the substantial safety data supporting the RaniPill platform, the value attributed to it remains modest, indicating a potential disconnect between market perception and commercial viability. Furthermore, the risk of failures in future clinical trials poses an additional threat to Rani's forecasts, further contributing to investor skepticism regarding the company’s long-term financial performance.

RANI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 4 analysts, RANI has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.